PUBLICATIONS

Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS

08 
Janurary

2021

Additional analyses of Efficacy and Safety of Pridopidine for Huntington’s Disease demonstrate positive effect on functional capacity

16 
December

2020 

Prilenia Enrolls First Patients into its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease in the United State

27
OCTOBER

2020 

Huntington Study Group Announces A Partnership with Prilenia Therapeutics to Conduct A Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease

17 
SEPTEMBER

2020 

Henk Schuring joins Prilenia as Chief Regulatory and Commercialization Officer

10 
SEPTEMBER

2020 

Prilenia Therapeutics raises $62.5M to fund late stage trials in HD and ALS

03
JUNE

2020

Presentation by Dr. Michael Hayden at the Jefferies
Virtual Conference 

03
JUNE

2020

18 
SEPTEMBER

2019 

Prilenia’s Pridopidine chosen to participate in the first ever ALS platform trial by the Sean M. Healey & AMG center for ALS at Mass General

 

PRESS RELEASES

CONTACT US

Email.  info@prilenia.com

Tel.  +972-77-5558482